Author Archives: Cerevast

Cerevast Therapeutics Inc., a privately held medical technology company, announced today that it has received CE mark clearance of its SonoLysis Headframe System, the Clotbust ER™ providing approval to commercialize the product in Europe. The Clotbust ER™ is a first-in-class … Continue reading →

Cerevast Therapeutics has recently completed the stroke treatment portion, Phase II, of the Combined Lysis of Thrombus in Brain Ischemia with Transcranial Ultrasound in Brain Ischemia (CLOTBUST-HF), an NIH funded Phase I/II trial. This phase of the study consisted of … Continue reading →

Cerevast Therapeutics has recently closed the first part of its Series “C” financing. Read the Notice of Exempt Offering of Securities on file with the U.S. Securities and Exchange commission.

Cerevast Therapeutics has recently completed the healthy volunteer phase of the Combined Lysis of Thrombus in Brain Ischemia with Transcranial Ultrasound in Brain Ischemia (CLOTBUST-HF), an NIH funded Phase I/II trial. In this initial phase of the study, 15 healthy … Continue reading →